Perioperative or postoperative adjuvant oxaliplatin with S-1 versus adjuvant oxaliplatin with capecitabine in patients with locally advanced gastric or gastro-oesophageal junction adenocarcinoma undergoing D2 gastrectomy (RESOLVE): an open-label, superiority and non-inferiority, phase 3 randomised controlled trialXiaotian Zhang, Jiafu Ji, Jiren Yu et al.|The Lancet Oncology|2021Cited by 436
The Neo-PLANET phase II trial of neoadjuvant camrelizumab plus concurrent chemoradiotherapy in locally advanced adenocarcinoma of stomach or gastroesophageal junctionZhaoqing Tang, Yihong Sun|Nature Communications|2022Cited by 82
High expression of CD39 in gastric cancer reduces patient outcome following radical resectionXiaoyan Cai, Yihong Sun|Oncology Letters|2016Cited by 57